Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 years or older
• People who have a confirmed diagnosis of smouldering multiple myeloma (SMM), a pre-cancer blood condition, based on specific laboratory findings showing abnormal protein levels or abnormal bone marrow plasma cell levels within a defined range
• People whose condition does not currently cause symptoms such as high calcium levels, anaemia, bone damage, or kidney problems linked to the plasma cell disorder
• People whose SMM is considered intermediate or high risk based on at least one or more specific blood and bone marrow measurements (confirm with trial site for exact thresholds)
• People with normal liver function, confirmed by blood tests done within 28 days before starting the trial
• People with adequate kidney function, confirmed by a specific calculation within 28 days before starting the trial
• People with adequate blood cell counts (white cells, red cells, and platelets) within 28 days before starting the trial
• People with a life expectancy of more than 12 months
• People who are in good general health, able to carry out normal daily activities with little to no restriction (a standard medical performance score of 0 or 1)
• People who are able to use two highly effective forms of contraception, or abstain from sex, throughout the trial and for 6 months after it ends (people who have had procedures making them unable to have children may be exempt)
• People who are able to understand and agree to the trial requirements

Who may not be able to join:

• People whose condition has progressed to active (symptomatic) multiple myeloma, indicated by high blood calcium, significant kidney problems, anaemia, bone lesions, very high levels of abnormal plasma cells in the bone marrow (60% or more), or very high abnormal protein levels in the blood
• People with a condition called systemic light chain amyloidosis (a related protein disorder affecting organs)
• People who regularly take corticosteroid medications (such as prednisone) at doses above 10mg per day for other health conditions
• People who have had an active invasive cancer within the past 3 years that could affect the trial results
• People who have had a non-invasive cancer within the past 3 years that was not treated with the aim of curing it, and that could affect the trial results
• People with an uncontrolled active infection that required intravenous antibiotics, antiviral, or antifungal treatment within 14 days before the first dose
• People with a known active HIV infection that is not being adequately managed with treatment
• People with active digestive system problems that prevent swallowing tablets or interfere with how the body absorbs medications
• People who are pregnant, breastfeeding, or planning to become pregnant within 6 months after finishing treatment
• People capable of having children who are not willing to use two highly effective forms of contraception during treatment and for 6 months after it ends
• People with a significant medical or psychiatric condition that, in the opinion of the trial doctors, may prevent them from completing the trial or affect the results
• People who have previously been treated with a type of drug called a SINE compound, including a drug called Selinexor

Important: Always verify eligibility with the trial site directly before applying.